Zentek Ltd. has announced its financial results for the second quarter of fiscal 2027, revealing a marked improvement in its financial position. The company ended the quarter with $13.6 million in cash, a significant increase from the $1.3 million it reported at the end of the previous fiscal year. This development is crucial for Zentek as it seeks to fund future projects, particularly in the Albany Graphite Project and its ZenGUARD™ product line.
The results, filed on November 17, 2026, highlight a shift in the company’s financial strategy, focusing on strengthening its balance sheet to support growth initiatives. The working capital has risen to $11.3 million, compared to a deficit of $1.3 million just six months prior. This turnaround is attributed to a financing round in May 2026, which provided approximately $16 million in net proceeds.
Background
Zentek Ltd., incorporated in Canada, operates within the miscellaneous chemical products sector (SIC 2890). The company is listed on the OTC exchange under the ticker ZTEKF. Zentek focuses on the development and commercialization of advanced materials, particularly in specialty materials, including its ZenGUARD™ coating for filters and personal protective equipment, as well as the Albany Graphite Project.
What the Filing Says
According to the filing, "Strengthening the balance sheet was a priority this year." The company reported total assets of $49.4 million, a substantial increase from $15.1 million at the end of the previous fiscal year. Additionally, Zentek has committed $1.2 million to the Albany Graphite Project, which includes completing a preliminary economic assessment (PEA) that has significantly improved the project's valuation.
Impact
This financial update is likely to influence various stakeholders, including investors, employees, and partners such as the Constance Lake First Nation, who are involved in the Albany Graphite Project. The improved financial health may enhance investor confidence and support further investments in the company's initiatives.
What's Next
The filing does not specify what happens next, but the company’s management has expressed a commitment to reducing risk and building value through disciplined capital deployment and strategic focus on its assets.
Read Next
Ryanair Announces First Engine MRO Facility in Seville
Equels Thomas K reports stock transaction for AIM ImmunoTech
Bally's Corp secures $560 million in new financing
Saideman reports stock transactions for Church & Dwight
Kevin J. Chan Reports Stock Transactions at Worthington
Edesa Biotech secures orphan designation for ARDS treatment





